FDA deals ISTA a blow

Article

ISTA Pharmaceuticals has received a not approvable letter from the FDA relating to its New Drug Application (NDA) for T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension).

ISTA Pharmaceuticals has received a not approvable letter from the FDA relating to its New Drug Application (NDA) for T-Pred (prednisolone acetate 1.0% and tobramycin 0.3% ophthalmic suspension).

T-Pred is a topical steroid developed for the treatment of inflammatory ocular conditions for which a corticosteroid is indicated and where bacterial ocular infections or a risk of bacterial infection exists.

A multicentre, randomized, double-blind study was conducted to determine bioequivalence of prednisolone concentrations between T-Pred and PredForte (prednisolone acetate 1.0%). ISTA believes that the study achieved or exceeded the goal, both in the intent-to-treat and the per-protocol patient populations. Furthermore, the company also believes that the study shows T-Pred to have antimicrobial activity equivalent to other combination products approved for this indication.

However, FDA assessment of the clinical data did not show sufficient equivalence between the prednisolone component in T-Pred and PredForte. ISTA disagrees with the findings and plans to request a meeting with the FDA as soon as possible to discuss the matter.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Omer Trivizki, MD, MBA, a retina specialist from Tel Aviv Medical Center, speaks about VOY-101, a Novel, Complement-Modulating Gene Therapy for Geographic Atrophy at the American Society of Retina Specialists (ASRS) Annual Meeting
João Pedro Marques, MD, MSc, PhD discusses a retrospective study of 800 patients with inherited retinal diseases during the American Society of Retina Specialists (ASRS) annual meeting
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
© 2025 MJH Life Sciences

All rights reserved.